

Please complete this **entire** form and fax it to: **866-940-7328**. If you have questions, please call **800-310-6826**.
This form may contain multiple pages. Please complete all pages to avoid a delay in our decision.
Allow at least 24 hours for review.

Section A – Member Information

First Name:	Last Name:	Member ID:
Address:		
City:	State:	ZIP Code:
Phone:	DOB:	Allergies:
Primary Insurance Information (if any):		
Is the requested medication: <input type="checkbox"/> New or <input type="checkbox"/> Continuation of Therapy? If continuation, list start date: _____		
Is this patient currently hospitalized? <input type="checkbox"/> Yes <input type="checkbox"/> No If recently discharged, list discharge date: _____		

Section B - Provider Information

First Name:	Last Name:	M.D./D.O.	
Address:	City:	State:	ZIP code:
Phone:	Fax:	NPI #:	Specialty:
Office Contact Name / Fax attention to:			

Section C - Medical Information

Medication:	Strength:
Directions for use:	Quantity:
Diagnosis (Please be specific & provide as much information as possible):	ICD-10 CODE:
Is this member pregnant? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, what is this member's due date? _____	

Section D – Previous Medication Trials

Medication Name	Strength	Directions	Dates of Therapy	Reason for failure / discontinuation

**Section E – Additional information and Explanation of why preferred medications would not meet the patient's needs:
Please refer to the patient's PDL for a list of preferred alternatives**

Member First name:	Member Last name:	Member DOB:
---------------------------	--------------------------	--------------------

Clinical and Drug Specific Information

ALL REQUESTS

<input type="checkbox"/> Yes <input type="checkbox"/> No	Is the request for continuation of prior therapy for a seizure disorder? <i>If yes, list start date:</i>
<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the patient have one of the following diagnoses? (If yes, check which applies) <input type="checkbox"/> Partial-onset seizures <input type="checkbox"/> Complex Partial seizures <input type="checkbox"/> Infantile Spasms
<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the patient have a diagnosis of partial-onset seizures with or without secondarily generalized seizures or primary generalized tonic-clonic seizures?
<input type="checkbox"/> Yes <input type="checkbox"/> No	Is there history of greater than or equal to 8 week trial of any of the following (any release formulation qualifies)? (If yes, check which applies and complete Section D above) <input type="checkbox"/> Carbamazepine <input type="checkbox"/> Divalproex <input type="checkbox"/> Gabapentin <input type="checkbox"/> Lamotrigine <input type="checkbox"/> Levetiracetam <input type="checkbox"/> Oxcarbazepine <input type="checkbox"/> Phenytoin <input type="checkbox"/> Pregabalin <input type="checkbox"/> Topiramate <input type="checkbox"/> Valproic acid <input type="checkbox"/> Zonisamide
<input type="checkbox"/> Yes <input type="checkbox"/> No	Is there <u>both</u> of the following? (If yes, check which applies and complete Section D above) <input type="checkbox"/> Documented history of persisting seizures after titration to the highest tolerated dose with each medication trial <input type="checkbox"/> Lack of compliance as a reason for treatment failure has been ruled out
<input type="checkbox"/> Yes <input type="checkbox"/> No	Is there <u>both</u> of the following? (If yes, check which applies and complete Section D above) <input type="checkbox"/> Documentation of failure due to intolerable side effects <input type="checkbox"/> Reasonable efforts were made to minimize the side effect (e.g. change timing of dosing, divide dose out for more frequent but smaller doses, etc.)

ONFI / BANZEL / FELBATOL

<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the patient have a diagnosis of seizures associated with Lennox-Gastaut syndrome (LGS)?
--	---

GABITRIL

<input type="checkbox"/> Yes <input type="checkbox"/> No	Will this be used as adjunctive therapy (defined as accessory treatment used in combination to enhance primary treatment)?
--	---

EPIDIOLEX

<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the patient have one of the following diagnoses? (If yes, check which applies) <input type="checkbox"/> Seizures associated with Dravet syndrome <input type="checkbox"/> Seizures associated with Lennox-Gastaut Syndrome
--	--

SABRIL

<input type="checkbox"/> Yes <input type="checkbox"/> No	Will Sabril be used as adjunctive therapy? <i>If yes, list medication:</i>
--	--

SYMPAZAN

<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the patient have one of the following diagnoses? (If yes, check which applies) <input type="checkbox"/> Seizures associated with Lennox-Gastaut syndrome (LGS) <input type="checkbox"/> Diagnosis of refractory partial onset seizures (four or more uncontrolled seizures per month after an adequate trial of at least two antiepileptic drugs)
<input type="checkbox"/> Yes <input type="checkbox"/> No	Is there <u>both</u> of the following? (If yes, check which applies and complete Section D above) <input type="checkbox"/> Used as adjunctive therapy (defined as accessory treatment used in combination to enhance primary treatment.) <input type="checkbox"/> Not used as primary treatment

Provider Signature: _____ **Date:** _____

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.